Axon Rises 23.3% in a Month: Should Investors Bet on the Stock Now?

Axon shares have risen 23.3% over the past month, supported by strong momentum in Connected Devices and Software & Services. First-quarter 2026 segment revenues grew 32.8% and 35.0%, while management raised full-year revenue growth guidance to 30-32% from 27-30%. Valuation remains a headwind at 52.75x forward P/E, but analyst estimates and growth outlook remain constructive.

Analysis

AXON’s relative strength is increasingly a function of operating leverage, not just narrative premium. The mix shift toward recurring software and consumables means each incremental deployment compounds lifetime value, while the hardware install base creates a multi-year attach-rate flywheel; that tends to make top-line revisions sticky even when the stock looks expensive on headline P/E. The important second-order effect is that stronger adoption also tightens ecosystem lock-in, raising switching costs for municipalities and agencies and making competitor displacement harder than simple product comparisons imply.

The valuation risk is less about absolute multiples and more about duration sensitivity: AXON is effectively a long-duration compounder trading like a growth asset, so any wobble in rates, index de-grossing, or a guidance reset can compress the multiple faster than earnings can grow into it. The stock sitting below its longer moving average suggests institutions are still waiting for another quarter of proof before re-rating it fully; that creates a tactical vulnerability if growth merely meets, rather than beats, the elevated bar. On the other hand, the earnings revision trend indicates sell-side models are still catching up to the mix improvement, so near-term estimate revisions can continue to support the name even without a new product catalyst.

The most underappreciated risk is execution on adjacent ventures: drones, counter-drone, and emergency-response integrations expand TAM, but they also broaden the surface area for integration delays, procurement scrutiny, and product-cycle slippage. Because these categories are more politically and operationally complex than core TASER/software, any headline around delayed deployments or a competitive win by a more specialized vendor would likely hit the multiple before it hits the numbers. In other words, the stock’s downside is likely to come from narrative damage and multiple compression, not an immediate revenue miss.

Key Decisions for Investors

• Prefer a tactical long only on weakness: accumulate AXON on a 5-10% pullback or after a post-earnings consolidation, targeting a 3-6 month re-rating if revenue growth stays >30%; risk is a 15-20% multiple compression if guidance merely in-lines.
• Use calls rather than stock for event exposure: buy 3-6 month AXON calls into the next earnings window to express upside convexity while limiting downside from valuation derating; best suited if implied vol is below historical post-print realized.
• Pair trade: long AXON / short TDY as a relative-growth expression over 2-4 quarters; AXON’s recurring software mix should outgrow TDY’s more mature industrial exposure, but size modestly because AXON’s multiple can still compress independently.
• Avoid chasing the breakout in outright equity until the stock reclaims its longer-term trend; if AXON fails to hold recent gains on the next market-wide risk-off day, that would signal institutional supply and a cleaner entry later.
• For more defensive positioning, hedge any AXON long with a small basket short in high-multiple government-tech names over 1-2 months; if growth stocks derate, AXON’s valuation risk will behave more like the basket than like its reported earnings growth.